Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade

Oncoimmunology. 2017 Jul 13;6(10):e1346766. doi: 10.1080/2162402X.2017.1346766. eCollection 2017.

Authors

Alejandro López-Soto¹, Segundo Gonzalez¹, Lorenzo Galluzzi^{2

3

4}

Affiliations

¹ Departamento de Biología Funcional, Área de Inmunología, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Asturias, Spain.
² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, US.
³ Sandra and Edward Meyer Cancer Center, New York, NY, US.
⁴ Université Paris Descartes/Paris V, Paris, France.

No abstract available

Keywords: CTLA4; MICB; NK cells; PD-1; immune checkpoint blockers; pembrolizumab.

Publication types

Editorial
Research Support, Non-U.S. Gov't